Brief: Paion - Submission Of New Drug Application In U.S
April 8 (Reuters) - Paion AG PA8G.DE :
* PAION ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION FOR
REMIMAZOLAM BY ITS LICENSEE COSMO PHARMACEUTICALS IN U.S
Source text in Eikon: urn:newsml:reuters.com:*:nEQ9jbSDya
Further company coverage: PA8G.DE
(Berlin Speed Desk)
((frankfurt.newsroom@thomsonreuters.com; +49 30 288 85 126;))
Recent news on PAION AG
See all newsBrief: Paion AG To Issue Approx 4.8 Mln Shares In Capital Increase With Subscription Rights
Brief: Paion AG Reports Developments On Commercial Activities In Europe
Brief: Paion Q1 EBITDA Up At EUR 15 Mln
Brief: Paion Grants Exclusive License To Cristália For Development And Commercialization Of Remimazolam In Latin America
Brief: Paion Announces Sebastian Werner As New CFO, Effective 1 June 2022